Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SCYX by emailGet an email when SCYX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SCYX, unsubscribe in one click. Privacy
📣 What SCYX Says Is Next
Q4 2026 · “SCYNEXIS is expected to begin a Phase 2 proof-of-concept study in ADPKD patients in Q4 2026, with an anticipated early efficacy readout in second half of 2027.”
Company press release, Mar 31, 2026 · SEC filing
Q4 2026 · “A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027”
Company press release, Mar 31, 2026 · SEC filing
H2 2027 · “Phase 2 POC initial readout expected in H2 2027 SCY-770 ALD and other Oral”
Company press release, Mar 31, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SCYX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCYX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.